We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Xceleron Executes Microdose Agreement with Resverlogix

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Xceleron Executes Microdose Agreement with Resverlogix"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Xceleron has announced an agreement with Resverlogix Corp., Canada to conduct a Phase 0 human microdose study on their lead molecule(s) for raising ‘good’ cholesterol levels to reduce plaque in the fight against cardiovascular disease.

The study’s purpose is to administer sub-pharmacological dose levels of promising drug candidates in human volunteers in order to gain critical pharmacokinetic information which in turn will enable the promising drug candidate(s) to be progressed to Phase I trials.

"We’re excited to be adding value to the Resverlogix development program by providing very early human data to aid candidate selection," said Scott Tarrant Xceleron Vice President, Business Development. 

"The Resverlogix agreement further adds to our North American partner portfolio and reflects the continuing increase in demand for microdosing that we highlighted earlier this month when we announced our US expansion plans," added Tarrant.

"Choosing our lead molecules for the first administration in man studies represents a major scientific step in our exciting path of development for our NexVas™ PR program," stated Don McCaffrey President and CEO of Resverlogix.

"We expect that by as early as Q1 2007 the study will have shown that the successful results from our animal models are representative for humans helping us to predict the ApoA-I raising properties in humans."